Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
Researchers at UNIGE have discovered a way to overcome resistance to chemotherapy in colorectal cancer, using an optimized combination of tyrosine kinase inhibitors. This breakthrough opens up new avenues for developing targeted therapies that can effectively treat patients with low five-year survival rates.
The study found that BRAF alterations, particularly Class I mutations like v600E, are associated with improved overall survival in adults with glioma. However, the effectiveness of targeted therapies depends on the specific type and combination of genetic alterations driving the cancer.
Researchers have developed a drug compound that stops cancer cell growth in mice with little effect on normal healthy cells, making it potentially nontoxic for patients. The therapy targets the epidermal growth factor receptor gene, which is overexpressed in about half of all triple-negative breast cancer cases.
A new Northwestern Medicine study identifies common and rare gene mutations that impact radiation resistance and sensitivity. This information will allow clinicians to better calibrate radiation doses based on genetic mutations, improving treatment efficacy while reducing toxicity.
Researchers at Duke University have developed a novel treatment that combines internal radiation and chemotherapy to eliminate tumors in 80% of mice with pancreatic cancer. The approach uses a gel-like depot implanted with radioactive iodine-131, which deposits beta radiation directly into the tumor without affecting surrounding tissue.
A recent study by Weill Cornell Medicine investigators found that corrupted endothelial cells can protect leukemia cells from chemotherapy drugs. The discovery has the potential to improve drug discovery programs and clinical trials for T-cell acute lymphoblastic leukemia (T-ALL) patients.
A novel polysorbate-based formulation enhances carboplatin's therapeutic response in lymph nodes, amplifying antitumor effects and increasing drug penetration.
Researchers developed a new machine-learning approach to classify macrophages, which are key immune cells involved in pro- or anti-inflammatory responses. This technology could be used as a diagnosis tool or to highlight the role of specific cell types in disease environments.
Researchers at LSU Health New Orleans have identified a new drug target for triple-negative breast cancer, which lacks estrogen and progesterone receptors. The novel small molecule inhibitor NSC33353 works synergistically with doxorubicin to suppress the growth of TNBC cells.
A new potential antitumor drug, TRIP, causes rapid protein aggregation, hyperactivating the unfolded protein response and leading to programmed cell death in ovarian cancer cells. The Fe-S cluster biogenesis factor NUBP2 is identified as the probable starting point for the cellular processes triggered by TRIP.
The study reveals how the activating partner PI5P interacts with two different regions of regulatory protein UHRF1, showing its role in modulating complex proteins. This finding could breathe new life into the search for UHRF1-directed medicines.
Researchers developed an AI model that analyzes immune cells to predict which skin cancer patients will benefit from treatments activating the immune system. The study found that patients with more immune cells recognizing skin cancer had better treatment outcomes.
A recent study found that cancer biomarker data is biased towards European populations, potentially misclassifying patients of Asian or African descent. The researchers propose a computational approach to correct this bias, which could have significant implications for treatment selection.
Researchers have developed a new approach to test the efficacy of multiple anticancer drug combinations simultaneously, rapidly, and accurately. Combi-seq overcomes limitations of conventional technologies by using microfluidics to carry out large-scale experiments with small sample volumes.
Scientists from NTU Singapore have discovered that telomeres are stacked in columns like a spring, leaving DNA exposed to damage. This finding could improve understanding of how humans age and develop cancer, with potential treatments for diseases caused by dysfunctional telomeres.
Recent media releases from UK government agencies and NHS organizations lack objectivity and provide unbalanced information on prescription-only medicines. The Drug and Therapeutics Bulletin expresses concerns over the use of hyperbolic language and omission of key information about potential harms and benefits.
Researchers at the University of Helsinki have identified target genes of the MYC oncogene responsible for its growth-promoting effects. By modifying these genomic binding sites, they slowed down cell growth. This finding has significant implications for developing new cancer treatments.
Researchers have identified a small molecule drug, SHP656, that can target the circadian clock proteins responsible for glioblastoma's recurrence and spread. The drug has shown promise in reducing cancer stem cell growth without harming normal stem cells.
A potential new treatment for glioblastomas, a deadly form of brain tumor, is being researched using the medication letrozole. Studies have shown that letrozole can be effective in killing tumor cells and reaching target tissue safely.
Mayo Clinic researchers identified critical genomic changes associated with abiraterone acetate/prednisone resistance in advanced prostate cancer. An 11-gene drug panel predicted a worse prognosis for a subset of patients, and whole-exome sequencing data revealed mechanisms of acquired resistance.
Researchers have developed a flexible endoscopic imaging probe using a bendable graded index (GRIN) lens, enabling 3D microscopic imaging of tissue. The new technology could shorten biopsy waiting times to minutes and enable real-time monitoring of tissue changes.
Researchers at UMC Utrecht will investigate how intestinal microbiota impacts cancer immunotherapy and therapy side effects. The project aims to develop microbiota-targeted therapies to improve ICI treatment effectiveness and reduce severe inflammation.
Researchers at Nagoya University have identified new agents involved in DNA damage tolerance pathways, including RFWD3, which may contribute to anticancer treatment. The study's findings suggest that inhibiting these pathways could sensitize cancer cells to conventional chemotherapeutic agents.
Researchers discovered a type of triple-negative breast cancer cell that can trigger dormancy, evading therapies and allowing for efficient survival in distant organs. This finding highlights the need for more selective therapeutic strategies targeting both dividing and invasive dormant cells.
Cancer cells become resistant to chemotherapies by slowing down DNA replication forks, allowing them to avoid collisions with chemotherapy drugs. A kinase called DNA-PKcs acts as a sensor when a fork is stressed and promotes slowing of the fork and chemo-resistance.
The new SIO-ASCO guideline recommends the use of acupuncture, massage therapy, and other integrative therapies for managing breast cancer-related joint pain, general cancer pain, and chemotherapy-induced peripheral neuropathy. The guidelines also acknowledge areas that need further research to support their recommendations.
Researchers discovered that autophagy facilitates the elimination of cancer cells via cell competition, highlighting its potential as a target for cancer prevention and treatment. The study sheds light on the role of autophagy in maintaining tissue homeostasis and opening avenues for novel anti-cancer therapeutics.
Researchers create a new, non-invasive wearable device that can measure tumor size changes in real-time. The 'Flexible Autonomous Sensor measuring Tumors' (FAST) device provides continuous monitoring and accurate results, offering a promising approach to cancer treatment.
A new wearable device called FAST can measure tumor size changes to the hundredth of a millimeter, providing a fast, accurate, and inexpensive way to test cancer drugs. This technology represents a significant advance in cancer treatment, offering continuous monitoring, flexibility, and non-invasiveness.
Researchers found that 12% of cancer survivors lived in poverty, experiencing negative effects on physical and mental health. Financial burden of cancer care persists years after diagnosis, leading to poor health outcomes and increased mortality.
Researchers at University of California - San Francisco have developed a new therapy that overcomes cancer cell barriers and marks them for destruction by the immune system. By pulling mutated KRAS protein to the surface, the drug acts as an “eat me” flag, allowing immunotherapy to eliminate all cells bearing this flag.
A study found that activation of the epidermal growth factor receptor (EGFR)-mediated signaling pathway is involved in lenvatinib resistance in thyroid cancer cells. Inhibition of EGFR by lapatinib therapy in combination with lenvatinib enhanced growth inhibitory effect and inhibited tumor growth more remarkably than monotherapy.
Researchers found that a specific sequence of drugs can reduce overall costs and improve the value of care for patients with metastatic breast cancer, while minimizing side effects. The study's results suggest that treatment sequencing approaches that minimize costs early may improve the value of care.
Scientists discover that methotrexate causes oxidative damage to the cerebrospinal fluid and choroid plexus, leading to cognitive impairment. Adding antioxidants to the CSF may protect against this damage, offering a potential treatment for 'chemo brain'. Researchers are exploring other chemotherapy drugs and testing antioxidant treatm...
In a Phase I/II trial, selpercatinib demonstrated a 44% objective response rate across multiple tumor types, including pancreatic and colorectal cancers. The study found responses regardless of cancer type or prior treatment history, confirming RET fusions as a tissue-agnostic target.
A new combination immunotherapy regimen shows remarkable activity in metastatic colorectal cancer patients without liver metastases, achieving a response rate of 40% and median overall survival exceeding 20 months. The study's findings confirm the importance of the tumor microenvironment in shaping the response to immunotherapy.
Bladder cancer researchers discovered a subset of CD8 T cells that adapts to tumor evasion strategies, offering a strategy to reduce tumor cells' ability to fight them off. The study also identified potential ways to make immunotherapy more effective against this deadly cancer by targeting the HLA-E/NKG2A axis.
Long-term opioid use after lung cancer surgery is associated with a 40% heightened death risk within two years, according to research. The study found that male sex, older age, and chemotherapy treatment are among the factors linked to long-term opioid use.
Researchers found that starting pembrolizumab before surgery significantly improves the outlook for patients with stage III-IV melanoma. The study showed a 42% lower event rate in patients receiving neoadjuvant therapy compared to those receiving adjuvant therapy.
A systematic review and meta-analysis of observational studies found a moderate association between antipsychotic use and an increased risk of breast cancer, estimated at over 30%. The study highlights the importance of risk-benefit assessment of antipsychotic prescription in high-risk patients.
A recent study published in Frontiers in Pediatrics suggests that modern immunotherapies, such as CAR-T cell therapy, could replace traditional stem cell transplantation for high-risk ALL patients. The review also discusses the importance of reducing long-term side effects, including organ damage and secondary cancers.
Researchers conducted a study on administering immunotherapy drug pembrolizumab before surgery for oral cavity cancer and found no increased rates of complications during and after surgery. The findings are encouraging for patients who have not previously received treatment for their oral cavity cancer, suggesting that complication rat...
Breast cancer recurrence and metastatic spread remain a significant challenge, with researchers identifying a metabolic signature that can predict patient outcomes. The signature could be used to develop new therapies targeting cancer metabolism.
A Saint Louis University researcher has identified a potential treatment for 'chemo-brain', a debilitating side effect of chemotherapy that affects patients' quality of life. The treatment targets the molecular events underlying this deficit and repurposes an already-approved FDA drug to reduce cognitive impairment.
A large Nordic study found that children born after frozen-thawed embryo transfer had a higher risk of cancer than those conceived naturally or through fresh embryo transfer. The most common types of cancer seen were leukemia and central nervous system tumors.
Researchers at Tel Aviv University develop a groundbreaking method to eradicate glioblastoma brain tumors by targeting astrocytes and starving them of energy. The study found that in the absence of these brain cells, tumor cells die and are eliminated, offering a promising basis for developing effective medications.
A newly identified link between chronic pain and lung cancer in mice suggests that old drugs such as clonidine, capsaicin, and fluphenazine may offer new treatments for chronic pain. The study found that blocking the BH4 pathway reduced pain sensitivity and decreased tumor growth in mouse models of KRAS-driven lung cancer.
Researchers have genetically engineered yeast to produce vindoline and catharanthine, the precursors to vinblastine, a widely used anti-cancer drug. This breakthrough may lead to new sources of these compounds and reduce dependence on plant farming and logistics challenges.
Researchers at the University of Gothenburg have identified a protein called HnRNPK that controls tumor growth by binding to messenger RNA, potentially enabling the development of new cancer drugs with fewer side effects.
A new preclinical model of thymic cancer reveals how a common mutation sparks tumor formation and identifies potential targets for therapy. The model, developed by Weill Cornell Medicine researchers, shares molecular characteristics with human thymic tumors, paving the way for new treatments.
A study from Lund University found that Caveolin-1 protein levels in surrounding tumour tissue affect breast cancer prognosis. The study suggests that this protein could be used as a marker for precise prognosis and treatment choice.
Researchers have found that an approved drug can block the CD39 enzyme, which protects cancer cells from the immune system. This could lead to new and more effective anti-cancer treatments by activating the body's own defenses against tumors.
Researchers at UVA have discovered the mechanism behind gene regulation during organ development, shedding light on how genetic material interacts with transcription factors to create different cell types. The study's findings could offer insights into the initiation of certain cancers and inspire new therapeutic development.
Recent evidence suggests hormone therapy at menopause does not significantly increase the risk of invasive breast cancer. However, estrogen combined with progesterone increases breast cancer risk for women with an intact uterus. Menopause experts offer reassurance to women and their healthcare providers about the safety of hormone ther...
Rice University researchers have developed a treatment combining drug factory implants producing interleukin-2 with checkpoint inhibitors to eradicate advanced-stage mesothelioma tumors in mice. The treatment resulted in complete tumor destruction in all seven treated mice, offering a promising approach to this aggressive lung cancer.
Researchers at Moffitt Cancer Center have discovered that cancer-associated fibroblasts can both promote and inhibit drug sensitivity in non-small cell lung cancer cells, depending on the type of tumor cell and drug used. The study suggests that targeting specific signaling pathways, such as the insulin-like growth factor (IGF) pathway...
Researchers found that using the drug erlotinib, which blocks a specific cancer pathway, led to a 30 percent reduction in polyps formed in patients with FAP. The study's findings suggest potential ways to prevent colorectal cancer in the general population at an earlier stage.
The study found an overall response rate of 57% and disease control rate of 83% in 23 patients with diverse cancer types. These results validate RET as a tissue-agnostic target with sensitivity to RET inhibition.
A comprehensive analysis of interstitial lung disease diagnosis and treatment in patients who received an antibody drug conjugate known as T-DXd found that close monitoring and proactive management can reduce the risk of ILD. The study results suggest that patient awareness and ongoing education can aid in early detection.
A recent study published in Cancer Research identified a unique vulnerability in certain high-risk cancers that can be exploited for targeted therapy. Researchers found that cancer cells with alternative lengthening of telomeres (ALT) have a common weakness, leading to resistance to DNA-damaging agents and chemotherapy.